Efficacy and influencing factor analysis of Voriconazole in the treatment of invasive fungal infections

Diagn Microbiol Infect Dis. 2023 Nov;107(3):116047. doi: 10.1016/j.diagmicrobio.2023.116047. Epub 2023 Aug 2.

Abstract

Current study aims to explore the correlation between the administered dose and efficacy of voriconazole in the treatment of invasive fungal infection (IFI). The correlation between different doses of Voriconazole and plasma concentrations as well as clinical efficacy was counted. Consequently, 40 strains of pathogenic micro-organisms were isoninelated and cultured from etiological samples. A total of 66 patients with steady-state trough serum concentrations ranging from 1.0 to 5.5 μg/mL were measured, with a compliance rate of 79.5%. Chi-square test showed that there was a significant correlation between Voriconazole steady-state serum trough concentration and treatment efficacy. In addition, the result of Pearson test showed that steady-state trough serum concentration of Voriconazole was significantly positively correlated with the administered dose (γ = 0.866, P < 0.001). On conclusion, Voriconazole is effective in treatment of IFI, and there is a significant dose-plasma concentration correlation with efficacy.

Keywords: Clinical efficacy; Invasive fungal infection; Trough serum concentration; Voriconazole.

MeSH terms

  • Antifungal Agents* / therapeutic use
  • Drug Monitoring
  • Humans
  • Invasive Fungal Infections* / drug therapy
  • Treatment Outcome
  • Voriconazole / therapeutic use

Substances

  • Voriconazole
  • Antifungal Agents